How is a molecular polymorphism defined?

Authors

  • Verena Schildgen,

    Dr. rer. nat.
    1. Hospital of the City of Cologne, University Hospital Witten-Herdecke, Institute of Pathology, Cologne, Germany
    Search for more papers by this author
  • Oliver Schildgen

    Prof. Dr. rer. nat., Corresponding author
    1. Hospital of the City of Cologne, University Hospital Witten-Herdecke, Institute of Pathology, Cologne, Germany
    • Kliniken der Stadt Köln gGmbH, Krankenhaus Merheim, Klinikum der Privaten Universität Witten/Herdecke Institut für Pathologie, Ostmerheimer Str. 200, D-51109 Köln, Germany; Fax: (011) 49 (0) 221-8907-3542

    Search for more papers by this author

Abstract

In this commentary, the authors address the question of how molecular polymorphisms are defined. Despite an overwhelming amount of literature reporting on single-nucleotide polymorphisms, there is still no harmonized definition of this term, which the authors believe is not acceptable in the area of personalized medicine.

We recently published a study in which we described a novel mutation in the phosphatidylinositol 3-kinase (PIK3CA) gene, which is involved in numerous cancers.1 During revision of the article, an interesting question of general interest in the area of molecular genetics arose.

The mutation frequency in our cohort was approximately 2% and we were asked if the mutation could in fact be a polymorphism rather than a mutation. In the search for a consensus definition of the term “polymorphism,” we discovered that any polymorphism is based on a mutation and that the frequency of the mutation needs to be between 1% and 10% of the investigated population, but there was no consensus definition for the term “polymorphism.” In turn, this observation means that a polymorphism is defined on the “gut feeling” of scientists rather than by hard scientific criteria. Moreover, there is no consensus regarding how large the population must be to identify a polymorphism as a polymorphism, thus leading to the problem that any mutation can become a rare polymorphism, provided the study cohort is large enough and the mutation is identified in “enough” individuals. In addition, a mutation or polymorphism could occur in both healthy individuals and those with cancer, but their frequencies may differ depending on the person's health status. Moreover, to the best of our knowledge, there is no information regarding to what extent a polymorphism may be based on the ethnic background of the study population; thus, a mutation in Asian patients may be a wild-type in a white population.

We believe that, in the area of genomics and personalized medicine, it is necessary to establish consensus definitions for the basic genetic terms that apply to all disciplines of molecular biology and that are accessible worldwide (eg, in the GenBank sequence database). Therefore, we would encourage harmonizing the definition of genetic terms.

FUNDING SUPPORT

No specific funding was disclosed.

CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosures.

Ancillary